Skip to main content

Advertisement

Table 4 Changes of bone turnover markers and BMD in the naïve and switch groups after 6 and 12 months of treatment

From: Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates

  Naïve group (n = 25) Switch group (n = 11)
Baseline 6 months P 12 months P Baseline 6 months P 12 months P
Total-PINP (ng/ml) 73.4 ± 5.5 30.6 ± 3.6 <0.05 32.5 ± 3.5 <0.05 36.8 ± 5.1 25.6 ± 3.8 n.s 29.9 ± 5.7 n.s
TRACP-5b (mU/dl) 426.2 ± 31.3 244.8 ± 27.6 <0.05 250.2 ± 22.4 <0.05 320.7 ± 21.0 278.4 ± 47.9 n.s 276.6 ± 40.0 n.s
ucOC (ng/ml) 4.1 ± 0.5 1.6 ± 0.2 <0.05 1.5 ± 0.2 <0.05 2.3 ± 0.6 1.1 ± 0.3 <0.05 1.4 ± 0.4 n.s
Spine BMD (g/cm2) 0.83 ± 0.04 0.88 ± 0.05 <0.05 0.89 ± 0.05 <0.05 0.85 ± 0.04 0.88 ± 0.04 <0.05 0.89 ± 0.04 <0.05
FN BMD (g/cm2) 0.60 ± 0.01 0.62 ± 0.01 <0.05 0.62 ± 0.01 <0.05 0.57 ± 0.03 0.59 ± 0.03 <0.05 0.59 ± 0.02 n.s
TH BMD (g/cm2) 0.62 ± 0.01 0.63 ± 0.02 n.s 0.64 ± 0.02 <0.05 0.62 ± 0.03 0.63 ± 0.03 n.s 0.63 ± 0.03 n.s
  1. Data are presented as means ± standard deviation (SD), Naïve group: treatment-naïve group; Switch group: transitioning from bisphosphonate group; BMD: bone mineral density; total-PINP: total-procollagen type I N-terminal propeptide; TRACP-5b: tartrate-resistant acid phosphatase-5b; ucOC: undercarboxylated osteocalcin; FN: femoral neck; TH: total hip. P values from Wilcoxon’s rank sum test for the change from baseline within each treatment group